It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.
Loviride's clinical significance is limited to patients participating in trials (e.g., CAESAR and AVANTI), where it was often used without a companion drug, leading to the development of reverse transcriptase mutations like K103N that confer resistance to NNRTIs such as efavirenz and nevirapine.